ATE74755T1 - Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. - Google Patents

Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Info

Publication number
ATE74755T1
ATE74755T1 AT86401442T AT86401442T ATE74755T1 AT E74755 T1 ATE74755 T1 AT E74755T1 AT 86401442 T AT86401442 T AT 86401442T AT 86401442 T AT86401442 T AT 86401442T AT E74755 T1 ATE74755 T1 AT E74755T1
Authority
AT
Austria
Prior art keywords
pyrrolidinylmethyl
allyl
methoxy
disease
parkinson
Prior art date
Application number
AT86401442T
Other languages
English (en)
Inventor
Denis Dr Besancon
Brenda Dr Costall
Robert J Dr Naylor
Peter Dr Jenner
Charles D Prof Marsden
Hill Denmark
Original Assignee
Ile De France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ile De France filed Critical Ile De France
Application granted granted Critical
Publication of ATE74755T1 publication Critical patent/ATE74755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT86401442T 1985-07-15 1986-06-30 Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. ATE74755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8510802A FR2584605B1 (fr) 1985-07-15 1985-07-15 Application du n-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulfamoyl benzamide dans le traitement de la maladie de parkinson
EP86401442A EP0210099B1 (de) 1985-07-15 1986-06-30 Verwendung von N-(1-Allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur Behandlung der Parkinson-Krankheit

Publications (1)

Publication Number Publication Date
ATE74755T1 true ATE74755T1 (de) 1992-05-15

Family

ID=9321301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86401442T ATE74755T1 (de) 1985-07-15 1986-06-30 Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Country Status (6)

Country Link
US (1) US4725618A (de)
EP (1) EP0210099B1 (de)
JP (1) JPS6219518A (de)
AT (1) ATE74755T1 (de)
DE (1) DE3684825D1 (de)
FR (1) FR2584605B1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342826A (en) * 1964-01-13 1967-09-19 Ile De France Heterocyclic aminoalkyl benzamides
FR2358892A1 (fr) * 1976-07-19 1978-02-17 Ile De France N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives
US4263316A (en) * 1978-10-11 1981-04-21 Societe D'etudes Scientifiques Et Industrielles De L'ile De France N-(1-Methyl-2-pyrrolidinylmethyl)-2,3-dimethoxy-5-methylsulfamoyl benzamide and its derivatives, methods of preparing them and their application to the treatment of troubles of the lower part of the body
FR2489327B1 (fr) * 1980-08-28 1984-05-18 Ile De France N (1 allyl 2 pyrrolidinyl methyl) 2 methoxy 4 amino 5 methylsulfa moyl benzamide, son procede de preparation et son application comme medicament

Also Published As

Publication number Publication date
FR2584605B1 (fr) 1988-06-17
JPS6219518A (ja) 1987-01-28
DE3684825D1 (de) 1992-05-21
EP0210099A2 (de) 1987-01-28
EP0210099B1 (de) 1992-04-15
EP0210099A3 (en) 1989-11-23
FR2584605A1 (fr) 1987-01-16
US4725618A (en) 1988-02-16

Similar Documents

Publication Publication Date Title
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE3780618D1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
AT380897B (de) Mischung zur pflege und reinigung von kontaktlinsen
ATE93721T1 (de) Verwendung von fluoxetin zur behandlung des diabetes.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
ATE74762T1 (de) Pharmazeutisches praeparat zur behandlung von stoerungen des fettstoffwechsels (hyperlipoproteinaemien).
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69327207D1 (de) Tryptamine zur Behandlung von Störungen der circadianen Rhythmik
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
FI900372A7 (fi) Aryyli- ja heteroaryylietanoli-pyridyylialkyyliamiinit, menetelmä niiden valmistamiseksi ja niiden käyttö suoritusta edistävinä aineina eläimillä ja liikalihavuuden hoitoon käytettävinä aineina
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE3671698D1 (de) Anordnung zur stimulation von akupunkturpunkten.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee